SecBot SecBot

ODTX

Odyssey Therapeutics, Inc.
Nasdaq· CIK 0001882782 Biotech & Drug Discovery
$19.30 −0.30 (−1.53%)
Oct 26 4:00 PM ET · prev $19.60
Market cap
$917.0M
Small cap
Consensus
Buy
92% Buy or better · 12 analysts
Median target
$35.00
+81% · range $27.00–44.00
Since first trade
+17.5%
from $16.42 · May 8
30 days
−10.1%
from $21.47
Range since listing
$15.56–28.76
−33% from high · low Jul 8
Avg volume 20D
254.1K
shares / day
Short interest
3.11M
≈6.5% of shares · +40.6%
Days to cover
5.6
at average volume
Insider net
+$26.2M
3 buyers · 1 seller · since May 11
New fund stakes
3
Q2 2026 13F · 0 exits
Filing reports
17
analyzed by SecBot
SecBot read BULLISH 2 reports · 90 days
Balance 0 bearish · 1 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/2
Strongest BULLISH Odyssey Therapeutics presented completed Phase 2a induction results for OD-001, a first-in-class oral RIPK2…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    3 insiders bought $26.2M at an average $18.00. 1 insider sold $12.9K. Price is 7% above their cost.

  • InstitutionsBULLISH

    Q2 2026: 3 added (3 new), 0 trimmed or exited. Largest new: Fmr $96.9M, Adage Capital Partners Gp, L.L.C $13.6M.

  • AnalystsBULLISH

    11 of 12 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.890 → −$0.930 over 90 days.

  • Short sellersBUILDING

    Short interest +40.6% to 3.11M shares. 5.6 days to cover, ≈6.5% of shares.

  • TrendDOWNTREND

    13% below its 50-day average.

Who's buying

13F· Q2 2026
3
new positions
0
exits
$123.9M
in new stakes
FundMoveSharesValue
FMR LLCNEW5,179,262$96.9M
ADAGE CAPITAL PARTNERS GP, L.L.C.NEW725,000$13.6M
VANGUARD CAPITAL MANAGEMENT LLCNEW720,440$13.5M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

12 analysts
Buy 92% rate it Buy or better
Strong Buy4Buy7Hold1Sell0Strong Sell0
12-month targets · 6 analysts

Price is below the lowest target. Median implies +81%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Oct 12, 2026UBS
INITIATE
INITIATEBuy
Oct 9, 2026Raymond James
INITIATE
INITIATEOutperform
Aug 27, 2026HC Wainwright & Co.
INITIATE
INITIATEBuy
Aug 7, 2026JP Morgan
MAINTAIN
MAINTAINOverweight
Jun 18, 2026Oppenheimer
REITERATE
REITERATEOutperform
Jun 2, 2026Cantor Fitzgerald
INITIATE
INITIATEOverweight

Insider ledger

Form 4
$26.2M
bought · 3 insiders
$12.9K
sold · 1 insider
+7.2%
vs their $18.00 cost
DateInsiderTypeValue
May 11, 2026
SR ONE CAPITAL MANAGEMENT, LLC
10%+ Owner
EXERCISE764,312 sh
May 11, 2026
SR ONE CAPITAL MANAGEMENT, LLC
10%+ Owner
CONVERT2,657,860 sh
May 11, 2026
SR ONE CAPITAL MANAGEMENT, LLC
10%+ Owner
CONVERT4,500,000 sh
May 11, 2026
SR ONE CAPITAL MANAGEMENT, LLC
10%+ Owner
EXERCISE484,395 sh
May 11, 2026
SR ONE CAPITAL MANAGEMENT, LLC
10%+ Owner
CONVERT1,614,650 sh
May 11, 2026
SR ONE CAPITAL MANAGEMENT, LLC
10%+ Owner
CONVERT200,000 sh
May 11, 2026
SR ONE CAPITAL MANAGEMENT, LLC
10%+ Owner
CONVERT1,899,984 sh
May 11, 2026
SR ONE CAPITAL MANAGEMENT, LLC
10%+ Owner
CONVERT2,374,981 sh

Earnings setup

Estimates
−$0.93
EPS estimate, this quarter
−4%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.93-$1.07–-$0.81+0.0%$0.00
Next Q-$1.01-$1.17–-$0.85+0.0%$0.00
Current FY-$4.11-$4.33–-$3.89+3.4%$0.00
Next FY-$4.36-$5.08–-$3.45+0.0%$0.00

Short side

FINRA· Sep 30, 2026
3,105,465
shares short
+40.6%
vs prior settlement
5.6
days to cover
≈6.5%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 20, 2026 SEC
Odyssey Therapeutics presented completed Phase 2a induction results for OD-001, a first-in-class oral RIPK2…
8-K — Impact 6/10
Sep 30, 2026 Short interest report
Short Interest: ODTX up 41% to 3.1M shares
Settlement 2026-09-30 | Days to cover: 5.63 | ≈6.46% of shares outstanding (est.)
Aug 4, 2026 SEC
Odyssey Therapeutics reported Q2 2026 financial results with a GAAP net loss of $52.8M, wider than the $41.2M loss in…
8-K — Impact 4/10
Jun 30, 2026 Inst.
FMR LLC — NEW
5,179,262 shares ($96.9M)
Jun 30, 2026 Inst.
ADAGE CAPITAL PARTNERS GP, — NEW
725,000 shares ($13.6M)
Jun 17, 2026 SEC
Odyssey Therapeutics reported Q1 2026 financial results with a net loss of $38.3M, essentially flat YoY, and no…
8-K — Impact 4/10
May 11, 2026 Insider
SR ONE CAPITAL MANAGEMENT, LLC acquired via exercise 764,312 shares
10%+ Owner
May 11, 2026 Insider
SR ONE CAPITAL MANAGEMENT, LLC disposed of 2,657,860 shares
10%+ Owner
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Sep 30, 2026
Short interest
Short Interest: ODTX up 41% to 3.1M shares
Settlement 2026-09-30 | Days to cover: 5.63 | ≈6.46% of shares outstanding (est.)
Aug 4, 2026
Earnings
Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Data from the Phase 2a monotherapy trial of OD-001 accepted for oral presentation at United European Gastroenterology Week in October
Jun 30, 2026
Short interest
Short Interest: ODTX up 34% to 1.8M shares
Settlement 2026-06-30 | Days to cover: 3.68 | ≈3.74% of shares outstanding (est.)
Jun 17, 2026
Earnings
Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Reported positive clinical proof-of-concept data for OD-001 in a Phase 2a monotherapy trial for moderate to severe ulcerative colitis.
Jun 15, 2026
Short interest
Short Interest: ODTX up 161% to 1.3M shares
Settlement 2026-06-15 | Days to cover: 4.75 | ≈2.80% of shares outstanding (est.)

SecBot reports

17 filings · 1 press release · 4 bullish · 0 bearish · 3 mixed · 10 neutral
All ODTX filing & press-release reports (18)